New clinical trial (not yet open) to watch

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma See Original Notice Here Identifier: NCT03041701 Sponsor: National Cancer Institute (NCI) Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Two types are embryonal RMS (ERMS) and alveolar…
Continue Reading »

Clinical Trial Now Recruiting: Patients with Recurrent or Refractory Solid Tumors or Sarcomas

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Official Title: A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab For information regarding Eligibility Criteria, Contacts and Locations, please…
Continue Reading »

New Phase 1 Clinical Trial – Dr. Timothy Cripe, Nationwide Children’s Hospital

Please read the information below for Dr. Cripe’s HSV1716 study. Please feel free to contact Melinda Lynn (see below) if you need additional information. Clinical Study for Children and Adults 7 to 30 Years Old With Refractory Non-CNS Solid Tumors What: This is a phase I dose escalation study of intratumoral or intravenous herpes simplex virus-1 mutant…
Continue Reading »

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Reposted from Facebook via Mimi Olsson For more information on this study - According to the website, the trial is currently recruiting participants. On November 19, at MD Anderson Cancer Hospital in Houston, Texas I became the first human being in history to receive cancer treatment by injecting a bacteria (clostridium novi ) directly into…
Continue Reading »
Skip to toolbar